carbamazepine has been researched along with mexiletine in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Anger, T; Madge, DJ; Mulla, M; Riddall, D | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abbadie, C; Dean, B; Duffy, JL; Felix, JP; Garcia, ML; Hoyt, SB; Jochnowitz, N; Kaczorowski, GJ; Karanam, BV; Li, X; London, C; Lyons, KA; Martin, WJ; McGowan, E; Parsons, WH; Priest, BT; Smith, MM; Tschirret-Guth, R; Warren, VA; Williams, BS | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Sen, S; Sinha, N | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Gries, FA; Ziegler, D | 1 |
| Brose, WG; Tanelian, DL | 1 |
| Fontaine, B | 1 |
| Ichikawa, K; Kiguchi, S; Kojima, M | 1 |
| Gebhart, GF; Joshi, SK; Kardos, S; Su, X | 1 |
| Clouse, AK; Eisennagel, SH; Jugus, MJ; Laping, NJ; Thorneloe, KS; Westfall, TD | 1 |
| Meijer, IA; Nizard, S; Robitaille, Y; Rossignol, E; Vanasse, M | 1 |
| Carbonara, R; Conte Camerino, D; Costanza, T; Desaphy, JF | 1 |
| Banach, M; Borowicz-Reutt, KK; Piskorska, B | 1 |
| Harada, S; Matsuura, W; Tokuyama, S | 1 |
5 review(s) available for carbamazepine and mexiletine
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
Topics: Amyotrophic Lateral Sclerosis; Analgesics; Anticonvulsants; Epilepsy; Humans; Ion Channel Gating; Models, Molecular; Mutation; Nerve Tissue Proteins; Neuroprotective Agents; Protein Binding; Sodium Channel Blockers; Sodium Channels; Stroke | 2001 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Ion-channel related muscular diseases].
Topics: Acetazolamide; Anti-Arrhythmia Agents; Anticonvulsants; Carbamazepine; Humans; Hypokalemic Periodic Paralysis; Ion Channels; Mexiletine; Mutation; Myotonia; Paralysis, Hyperkalemic Periodic; Phenytoin; Potassium Chloride | 1999 |
An atypical case of SCN9A mutation presenting with global motor delay and a severe pain disorder.
Topics: Carbamazepine; Child, Preschool; Comorbidity; Erythromelalgia; Female; Humans; Hypesthesia; Mexiletine; Motor Skills Disorders; Mutation, Missense; NAV1.7 Voltage-Gated Sodium Channel; Severity of Illness Index; Somatoform Disorders; Treatment Outcome | 2014 |
18 other study(ies) available for carbamazepine and mexiletine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Imidazopyridines: a novel class of hNav1.7 channel blockers.
Topics: Analgesics; Animals; Inflammation; Molecular Structure; NAV1.7 Voltage-Gated Sodium Channel; Pain; Pyridines; Rats; Sodium Channel Blockers; Sodium Channels; Structure-Activity Relationship | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
[Treatment of pain in diabetic polyneuropathy].
Topics: Analgesics; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Carbamazepine; Diabetic Neuropathies; Gangliosides; Humans; Lidocaine; Linolenic Acids; Mexiletine; Pain | 1991 |
Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine.
Topics: Adult; Aged; Carbamazepine; Female; Humans; Lidocaine; Male; Mexiletine; Neuralgia; Peripheral Nerve Injuries; Sodium Channels | 1991 |
Suppressive effects of oxcarbazepine on tooth pulp-evoked potentials recorded at the trigeminal spinal tract nucleus in cats.
Topics: Analgesics, Opioid; Animals; Anti-Arrhythmia Agents; Anticonvulsants; Carbamazepine; Cats; Dental Pulp; Dibenzazepines; Electric Stimulation; Evoked Potentials; Female; Male; Mexiletine; Microinjections; Morphine; Oxcarbazepine; Polyethylene Glycols; Synaptic Transmission; Trigeminal Nucleus, Spinal | 2001 |
Sodium channel blocking actions of the kappa-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Anti-Arrhythmia Agents; Carbamazepine; Dynorphins; Male; Membrane Potentials; Mexiletine; Neurons, Afferent; Nociceptors; Pelvis; Peptide Fragments; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Sodium Channel Blockers; Stereoisomerism | 2002 |
Voltage-gated Na+ channel blockers reduce functional bladder capacity in the conscious spontaneously hypertensive rat.
Topics: Amitriptyline; Animals; Carbamazepine; Female; Lamotrigine; Mexiletine; Rats; Rats, Inbred SHR; Receptors, Muscarinic; Sodium Channel Blockers; Sodium Channels; Triazines; Urinary Bladder, Overactive; Urodynamics | 2012 |
Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
Topics: Animals; Carbamazepine; Disease Models, Animal; Flecainide; HEK293 Cells; Humans; Mexiletine; Muscle, Skeletal; Myotonia Congenita; Orphenadrine; Piperidines; Propafenone; Rats; Rats, Wistar; Riluzole; Sodium Channel Blockers; Thiazoles | 2014 |
Mexiletine and its Interactions with Classical Antiepileptic Drugs: An Isobolographic Analysis.
Topics: Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Drug Interactions; Electroshock; Male; Memory, Long-Term; Mexiletine; Mice; Motor Activity; Phenobarbital; Phenytoin; Seizures; Tissue Distribution; Valproic Acid | 2016 |
Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia.
Topics: Amines; Analgesics; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents, Tricyclic; Brain Ischemia; Carbamazepine; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Cyclopropanes; Gabapentin; gamma-Aminobutyric Acid; Hyperalgesia; Imipramine; Indomethacin; Male; Mexiletine; Mice; Milnacipran; Morphine; Neuralgia; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2016 |